Sofwave Medical Reports Record Second Quarter and First Half 2025 Financial Results and Business Highlights
MWN-AI** Summary
Sofwave Medical Ltd (TASE: SOFW), a leader in non-invasive aesthetic medical devices, reported impressive financial results for the second quarter and first half of fiscal year 2025, highlighting its strong growth trajectory. The company achieved record quarterly revenue of $21 million in Q2, reflecting a remarkable 43% year-over-year increase, while total revenue for the first half reached $37.7 million, up 35% compared to the previous year.
A noteworthy component of this success was the surge in recurring revenue, which totaled $9.2 million in Q2, marking a significant 53% growth and constituting 44% of total revenue. Sofwave’s robust financial health is underscored by an IFRS gross margin of 75.5% for Q2 and 75.9% for the first half, alongside positive operating and net income figures—contrasting with losses in the same period of the previous year.
The company generated $3.6 million in cash in Q2 and maintained a solid cash position of $24 million as of June 30, 2025. CEO Louis Scafuri emphasized the importance of the company's proven business model and its expanding market presence, powered by an increasing number of FDA clearances that support various aesthetic treatments. Notably, Sofwave has completed over 600,000 treatments since launch and garnered over one million social media followers, indicating growing brand engagement.
The company also sees significant potential in the rapidly evolving aesthetic market, with Dr. Shimon Eckhouse, Chairman of the Board, citing an adoptive consumer trend and ongoing demand for its innovative treatments. As it moves further into 2025, Sofwave aims to achieve operational break-even, bolstered by its lean infrastructure and strategic initiatives in the aesthetic treatment space.
MWN-AI** Analysis
Sofwave Medical Ltd (TASE: SOFW) has reported impressive financial results for the second quarter and the first half of fiscal 2025, indicating strong operational momentum in the non-invasive aesthetic medical device industry. The company achieved record revenues of $21 million in Q2, marking a significant 43% increase year-over-year. Recurring revenue also soared by 53% to $9.2 million, making up 44% of total revenue, which underscores the increasing consumer loyalty and wide acceptance of its innovative products.
The gross margin remained robust at 75.5%, demonstrating the company's efficiency in managing its operational costs even amid scaling operations. Notably, Sofwave achieved both IFRS and Non-IFRS net income, a noteworthy recovery from previous losses—indicating a successful turnaround strategy. The generated cash of $3.6 million in Q2 further strengthens its liquidity position, with cash and cash equivalents reaching $24 million as of June 30, 2025.
The market impact of the company’s diverse FDA clearances and expanding global presence—including regulatory clearance in Japan—positions Sofwave favorably to capitalize on the growing demand for non-invasive aesthetic treatments. The burgeoning social media following exceeding 1 million indicates rising brand awareness that may enhance customer engagement and retention.
Investors should consider Sofwave's consistent revenue growth, strong gross margins, and a promising outlook for achieving operating break-even by year-end. The projected organic growth driven by increased treatment capabilities and new product launches aligns well with industry trends. However, potential market volatility should be monitored, especially with evolving competitive pressures. Overall, Sofwave presents a compelling investment opportunity in a dynamic health and beauty sector, reinforcing its standing as a leader in aesthetic innovation.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
• Quarterly record revenue in Q2 of $21M, +43% year-over-year growth; IFRS gross margin of 75.5%
• Second quarter pulse recurring revenue of $9.2M, +53% year-over-year growth
• First half revenue of $37.6M, +35% year-over-year growth; IFRS gross margin of 75.9%
• Generated $3.6M in cash in the second quarter
• Positive first half and second quarter IFRS and Non-IFRS operating and net income vs first half loss in the same year ago period
• Over 600,000 treatments completed since inception; over 1 million followers on social media
SAN CLEMENTE, Calif., Aug. 05, 2025 (GLOBE NEWSWIRE) -- Sofwave Medical Ltd (TASE: SOFW), an emerging leader in energy-based non-invasive, aesthetic medical devices for practitioners worldwide, reported financial results for the second quarter and first half of fiscal year 2025, for the period ended June 30, 2025, and recent business highlights.
Second Quarter and First Half Fiscal 2025 Financial Highlights
- Second Quarter Revenue of $21M, representing 43% year-over-year growth
- Recurring Revenue of $9.2M, a year-over-year increase of 53%, representing 44% of total revenue
- Gross Profit was $15.9M, a year-over-year increase of 42%
- IFRS Gross Margin: 75.5%; *Non-IFRS 75.6%
- IFRS Operating Income: $2.2M, up from ($1.2M) in second quarter of 2024; *Non-IFRS: $2.9M
- IFRS Net Income: $1.5M; up from ($1.5M) in second quarter of 2024; *Non-IFRS: $2M
- First Half Revenue of $37.7M, representing 35% year-over-year growth
- Recurring Revenue of $16.2M, a year-over-year increase of 51%, representing 43% of total revenue
- Gross Profit was $28.6M, a year-over-year increase of 36%
- IFRS Gross Margin: IFRS 75.9%; *Non-IFRS 75.9%
- IFRS Operating Income: $1.2M; *Non-IFRS: $2.7M
- IFRS Net Income: $0.4M; *Non-IFRS: $2.0M
- Cash and Cash Equivalents as of June 30, 2025: $24.0M; generated $3.6M in cash in the second quarter of 2025
Management Commentary
Mr. Louis Scafuri, Sofwave CEO, commented, “We delivered record quarterly revenue of $21 million in the second quarter, representing 43% year-over-year growth and positioning us strongly as we enter the second half of fiscal 2025. On the bottom line, we generated both IFRS and Non-IFRS operating and net income, and we continue to expect to achieve operating break-even for the full year. Our proven business model is delivering solid ROI for our providers, fueling strong customer loyalty and expansion within existing accounts. Our broad range of FDA clearances—including lifting, laxity and wrinkle treatment on the face and neck, cellulite, acne scars, arm laxity, and muscle toning—is driving rapid industry adoption. Looking ahead, we have a scalable, lean infrastructure in place to support continued high growth and profitability. Our consistent operational execution, combined with rapidly expanding brand awareness—now surpassing 1,000,000 social media followers—is reinforcing Sofwave’s position as a category leader in non-invasive aesthetic innovation.”
Dr. Shimon Eckhouse, Chairman of the Board, added: “Sofwave continues to deliver next-generation patented energy based non-invasive aesthetic skin treatments that are disrupting an industry with outdated solutions. Our significant recurring revenue, now over 40% of total revenue, is indicative of the high level of satisfaction from patients and providers. with approximately 600,000 treatments that have been conducted with our technology since commercial launch, and key trends, like the widespread use of GLP-1 inhibitors, continue to drive demand for Sofwave’s skin lifting and muscle toning treatments. Importantly, we also continue to demonstrate operating expense discipline and maintain a strong balance sheet."
Recent Operational Highlights
- Sofwave’s liftHD body applicator debuts at the 44th Annual Meeting of the American Society for Laser Medicine and Surgery (ASLMS) 2025
- Sofwave’s SUPERB™ non-invasive akin treatment technology receives regulatory clearance in Japan significantly expanding its coverage of the APAC region
- Approximately 600,000 treatments have been conducted since initial market approval
- Reiterating Company will achieve operating break-even in 2025
Financial Summary (Q2 FY’25)
| IFRS Results (U.S. dollars in thousands) | ||
| Q2 2025 | Q2 2024 | |
| Revenue | $20,990 | $14,642 |
| Gross Profit | $15,854 | $11,148 |
| Gross Margin | 75.5% | 76.1% |
| Operating Income | $2,179 | ($1,213) |
| Net Income | $1,517 | ($1,530) |
| *Non-IFRS Results (U.S. dollars in thousands) | ||
| Q2 2025 | Q2 2024 | |
| Gross Profit | $15,859 | $11,166 |
| Gross Margin | 75.6% | 76.3% |
| Operating Profit/ (Loss) | $2,887 | ($554) |
| Net Income | $2,225 | ($871) |
(*) Excluding stock-based compensation.
About
Sofwave Medical Ltd. has implemented an innovative approach to wrinkle reduction lifting and cellulite using its proprietary breakthrough technology. SUPERB™, Synchronous Ultrasound Parallel Beam technology, is FDA-cleared to improve facial lines and wrinkles, lifting the eyebrow and lifting lax submental tissue (beneath the chin), lifting lax skin in the arms, as well as the short-term improvement in the appearance of cellulite and treatment of acne scars. The company’s Pure Impact™ module uses EMS technology and is cleared for muscle toning. Sofwave’s products provide physicians with smart yet simple, effective, and safe aesthetic solutions for their patients. Contact: Info@sofwave.com
Investor Contact:
Brian Ritchie
LifeSci Advisors LLC
(212) 915-2578
britchie@lifesciadvisors.com
FAQ**
How does Sofwave Medical Ltd Ord SOFWF plan to sustain its impressive 43% year-over-year revenue growth, particularly in the face of increased competition in the non-invasive aesthetic device market?
With recurring revenue now at 44% of total revenue, what strategies are in place at Sofwave Medical Ltd Ord SOFWF to further enhance customer loyalty and retention in this sector?
Given the rapid expansion into the APAC region with regulatory clearance in Japan, what are the projected impacts on revenue growth for Sofwave Medical Ltd Ord SOFWF in upcoming quarters?
As Sofwave Medical Ltd Ord SOFWF aims for operating break-even in 2025, what specific cost-reduction measures and operational efficiencies are being implemented to achieve this goal?
**MWN-AI FAQ is based on asking OpenAI questions about SofWave Medical Ltd Ord (OTC: SOFWF).
NASDAQ: SOFWF
SOFWF Trading
0.0% G/L:
$10.90 Last:
150 Volume:
$10.90 Open:
